Dr. Carol Shields Notes Possible Paradigm Shift in Treatment for Uveal Melanoma

Dr. Carol Shields, Chief of the Ocular Oncology Service at Wills Eye, will be involved with the Phase 2 clinical trial of a new neoadjuvant and an adjuvant treatment for uveal melanoma patients. "The preliminary clinical data shows clear evidence of anti-tumor activity and supports further clinical evaluation to determine the potential to either save the eye by avoiding enucleation, or to reduce the tumor thickness in the eye, enabling treatment with less radiation to preserve vision.

Read the story in Ophthalmology Times.